Why biotechs are feeling the bite

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, CFO, Special Advisor & Board Member of several biotech companies, including Portage Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:

• Allan’s updated view on what is happening in the market since he was on the show last summer and his own change in investment focus
• Why a downturn, negative enterprise value, and cash burn for many biopharma and biotech firms signals an opportunity for others
• A new breed of slimmer, capital-efficient biotechs that will have a reliance on outsourcing built into their de-risk strategy
• Why the capital-intensive CGT area is not always a sure thing - investment tips from someone that has helped raised more than $4 billion in funds

Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audits and two compensation committees.

He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing; an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.